Recruited brain tumor-derived mesenchymal stem cells contribute to brain tumor progression

Stem Cells

Volumn 32, Issue 5, 2014, Pages 1110-1123

  Behnan, Jinan ^a,b   Isakson, Pauline ^c   Joel, Mrinal ^a,c   Cilio, Corrado ^b   Langmoen, Iver A ^a   Vik Mo, Einar O ^a   Badn, Wiaam ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Cell adhesion molecules; Cell biology; Cell culture; Cell migration; Cell surface markers; Glioma; Mesenchymal stem cells; Multipotential differentiation; Recruited cells

Indexed keywords

ADAPALENE; CD11B ANTIGEN; CD31 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR6; ENDOGLIN; GREEN FLUORESCENT PROTEIN; NESTIN; TRANSCRIPTION FACTOR SOX2; VASCULAR CELL ADHESION MOLECULE 1; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CD9 ANTIGEN; CHEMOKINE RECEPTOR CXCR; CXCR4 PROTEIN, MOUSE; CXCR6 PROTEIN, MOUSE; HERMES ANTIGEN;

ADHERENT CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL INFILTRATION; CELL POPULATION; CELL PROLIFERATION; CELL SELECTION; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MOUSE; NEURAL STEM CELL; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; TUMOR BIOPSY; TUMOR CELL; TUMOR CELL LINE; TUMOR GROWTH; ANIMAL; BRAIN; BRAIN TUMOR; CELL CULTURE; CONFOCAL MICROSCOPY; DISEASE COURSE; FLOW CYTOMETRY; GENETICS; HEK293 CELL LINE; IMMUNOPHENOTYPING; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; MULTIPOTENT STEM CELL; PATHOLOGY; SURVIVAL; TRANSGENIC MOUSE;

ACTIVATED-LEUKOCYTE CELL ADHESION MOLECULE; ANIMALS; ANTIGENS, CD44; ANTIGENS, CD9; BRAIN; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELLS, CULTURED; DISEASE PROGRESSION; FLOW CYTOMETRY; GLIOMA; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; IMMUNOPHENOTYPING; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, TRANSGENIC; MICROSCOPY, CONFOCAL; MULTIPOTENT STEM CELLS; RECEPTORS, CXCR; RECEPTORS, CXCR4; SURVIVAL ANALYSIS;

EID: 84899011003     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1614     Document Type: Article

References (58)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
2. Hadjipanayis CG, Van Meir EG,. Tumor initiating cells in malignant gliomas: biology and implications for therapy. J Mol Med 2009; 87: 363-374.
3. Lagasse E, Shizuru JA, Uchida N, et al. Toward regenerative medicine. Immunity 2001; 14: 425-436.
4. A. J. Friedenstein, RKC, K. S. Lalykina,. The development of fibroblast colonies in monolayer cultures of guinea-pic bone marrow and spleen cells. Cell Tissue Kinet 1970; 3: 393-403.
5. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-317.
6. Morikawa S, Mabuchi Y, Kubota Y, et al. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J Exp Med 2009; 206: 2483-2496.
7. Taichman RS, Wang Z, Shiozawa Y, et al. Prospective identification and skeletal localization of cells capable of multilineage differentiation in vivo. Stem Cells Dev 2010; 19: 1557-1570.
8. Phinney DG, Prockop DJ,. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells 2007; 25: 2896-2902.
9. Yoshida T, Matsuda Y, Naito Z, et al. CD44 in human glioma correlates with histopathological grade and cell migration. Pathol Int 2012; 62: 463-470.
10. Jijiwa M, Demir H, Gupta S, et al. (2011) CD44v6 Regulates Growth of Brain Tumor Stem Cells Partially through the AKT-Mediated Pathway. PLoS ONE 2011; 6 (9).
11. Kijima N, Hosen N, Kagawa N, et al. CD166/activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion. Neuro Oncol 2012; 14 (10): 1254-64.
12. Kang SG, Shinojima N, Hossain A, et al. Isolation and perivascular localization of mesenchymal stem cells from mouse brain. Neurosurgery 2010; 67: 711-720.
13. Nakamizo A, Marini F, Amano T, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005; 65: 3307-3318.
14. Bexell DGS, Tormin A, Darabi A, et al. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther 2009; 17: 183-190.
15. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449: 557-63.
16. Houghton J, Stoicov C, Nomura S, et al. Gastric cancer originating from bone marrow-derived cells. Science 2004; 306: 1568-1571.
17. Klopp AH, Gupta A, Spaeth E et al. Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells 2011; 29 (1): 11-9.
18. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9: 157-173.
19. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
20. Debacq-Chainiaux F, Erusalimsky JD, Campisi J, et al. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 2006; 4: 1798-1806.
21. Murrell W, Palmero E, Bianco J et al. Expansion of multipotent stem cells from the adult human brain, Plos One 2013; 8 (8): e71334.
22. Zagzag D, Armirnovin R, Greco MA, et al. Vascular apoptosis and evolution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab Invest 2000; 80: 837-49.
23. Lee J, S Kotliarova, Y Kotliarov, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006; 9: 391-403.
24. Vik-Mo EO, Sandberg C, Olstorn H, et al. Brain tumor stem cells maintain overall phenotype and tumorigenicity after in vitro culturing in serum-free conditions. Neuro Oncol 2010; 12: 1220-30.
25. S Pellegatta, P L Poliani, et al. Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res 2006; 66: 21. 10247-52.
26. Jung Y, Kim J, Shiozawa Y, et al. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nature Communications 2013; 4: 1795.
27. Newcomb EW, Zagzag D,. The Murine GL261 glioma experimental model to assess novel brain tumor treatments. In:, Van Meir EG, (ed). Cancer Drug Discovery and Development. Humana Press: Atlanta, GA 2009; 227-241.
28. Maes W, Van Gool SW,. Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model. Cancer Immunol Immunother 2011; 60 (2): 153-60.
29. Wu A, Oh S, Wiesner SM, et al. Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cells Dev 2008; 17: 173-184.
30. Lottaz C, D Beier, K Meyer, et al. Transcriptional profiles of CD133+ and CD133-glioblastoma-derived cancer stem cell lines suggest different cells of origin. Cancer Res 2010; 70: 2030-2040.
31. Soda Y, Marumoto T, Friedmann-Morvinski D, et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U S A 2010; 108: 4274-4280.
32. Capes-Davis A, Theodosopoulos G, Atkin I, Drexler HG, Kohara A, et al. Check your cultures! A list of cross-contaminated or misidentified cell lines. International Journal Of Cancer 2010; 127: 1-8.
33. Rappa G, Mercapide J, Anzanello F, et al. Growth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets. Exp Cell Res 2008; 314: 2110-2122.
34. Ho IA, Toh HC, Ng WH, et al. Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. Stem Cells 2013; 31 (1): 146-55.
35. Waterman RS, Henkle SL, Betancourt AM,. Mesenchymal Stem Cell 1 (MSC1)-Based Therapy Attenuates Tumor Growth Whereas MSC2-Treatment Promotes Tumor Growth and Metastasis. Plos One 2012; 7 (9): e45590.
36. Nauta AJ, Fibbe WE,. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110: 3499-506.
37. Spaggiari GM, Capobianco A, Becchetti S, et al. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006; 107: 1484-90.
38. Sotiropoulou PA, Perez SA, Gritzapis AD, et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74-85.
39. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42-8.
40. Di Nicola M, Carlo-Stella C, Magni M, et al. Human bone marrow stromal cells suppress Tlymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-43.
41. Potian JA, Aviv H, Ponzio NM, et al. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 2003; 171: 3426-34.
42. Welm BE, Tepera SB, Venezia T, et al. Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population. Dev Biol 2002; 245: 42-56.
43. Upadhyay G, Yin Y, Yuan H, et al. Stem cell antigen-1 enhances tumorigenicity by disruption of growth differentiation factor-10 (GDF10)-dependent TGF-beta signaling. Proc Natl Acad Sci U S A 2011; 108: 7820-7825.
44. Batts TD, Machado HL, Zhang Y, et al. Stem Cell Antigen-1 (Sca-1) Regulates Mammary Tumor Development and Cell Migration. Plos One 2011; 6 (11): e27841.
45. Ehtesham M, Min E, Issar NM, et al. The role of the CXCR4 cell surface chemokine receptor in glioma biology. J Neurooncol 2013; 14 (10): 1007/s11060-013-1108-4.
46. Wang J, Gu Z, Ni P, et al. NF-kappaB P50/P65 hetero-dimer mediates differential regulation of CD166/ALCAM expression via interaction with micoRNA-9 after serum deprivation, providing evidence for a novel negative auto-regulatory loop. Nucleic Acids Res 2011; 39: 6440-6455.
47. Tan X, Wang S, Yang B, et al. (2012) The CREB-miR-9 Negative Feedback Minicircuitry Coordinates the Migration and Proliferation of Glioma Cells. Plos One 2012; 7 (11): e49570.
48. Meijer J, Ogink J, Kreike B, et al. The CXCL16-CXCR6 chemokine axis in glial tumors. J Neuroimmunol 2013; 260 (1-2): 47-54.
49. Schraivogel D, Weinmann L, Beier D, et al. CAMTA1 is a novel tumour suppressor regulated by miR-9/9* in glioblastoma stem cells. EMBO J 2011; 30: 4309-4322.
50. Kim SM, Kang SG, Park NR, et al. Presence of glioma stroma mesenchymal stem cells in a murine orthotopic glioma model. Childs Nerv Sys 2011; 27 (6): 911-22.
51. Yu JM, ES Jun, YC Bae, and, JS Jung,. Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Stem Cells Dev 2008; 17: 463-473.
52. Akimoto K, Kimura K, Nagano M, et al. Umbilical Cord Blood-Derived Mesenchymal Stem Cells Inhibit, But Adipose Tissue-Derived Mesenchymal Stem Cells Promote, Glioblastoma Multiforme Proliferation. Stem Cells Dev 2013; 22 (9).
53. Machein MR, Renninger S, de Lima-Hahn E, et al. Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathol 2003; 13: 582-97.
54. Zhou YF, Bosch-Marce M, Okuyama H, et al. Spontaneous transformation of cultured mouse bone marrow-derived stromal cells. Cancer Res 2006; 66: 10849-10854.
55. Schichor C, Albrecht V, Korte B, Buchner A, et al. Mesenchymal stem cells and glioma cells form a structural as well as a functional syncytium in vitro. Exp Neurol 2012; 234 (1): 208-19.
56. Mercapide J, Rappa G, Anzanello F, et al. Primary gene-engineered neural stem/progenitor cells demonstrate tumor-selective migration and antitumor effects in glioma. Int J Cancer 2010; 1:126(5): 1206-15.
57. Goldenberg DM,. Ü ber die Progression der Malignita ät: Eine Hypothese [on the progression of malignancy: a hypothesis]. Klin Wochenschr 1968; 46: 898-9.
58. Goldenberg DM, Zagzag D, Heselmeyer-Haddad KM, et al. Horizontal transmission and retention of malignancy, as well as functional human genes, after spontaneous fusion of human glioblastoma and hamster host cells in vivo. Int J Cancer 2012; 131 (1): 49-58.